PROGRAM ANNOUNCEMENT (PA) TITLE: THE FETAL BASIS OF ADULT DISEASE: ROLE OF THE
ENVIRONMENT
PAR NUMBER: PAR-02-105 (see replacement PAR-03-121)
RELEASE DATE: May 2, 2002
Letter of Intent Receipt Dates: July 10, 2002, 2003, 2004
Application Receipt Dates: August 12, 2002, 2003, 2004
This Program Announcement expires on August 13, 2004, unless reissued.
PARTICIPATING INSTITUTES AND CENTERS (ICs)
National Institute of Environmental Health Sciences (NIEHS)
(http://www.niehs.nih.gov)
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of this PA
o Research Objectives
o Mechanism of Support
o Eligible Institutions
o Funds Available
o Individuals Eligible to Become Principal Investigators
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS PA
It is recognized that between two-percent and five-percent of all live-born
infants have a major developmental defect. Approximately 40-percent of these
defects are thought to be due to the effect(s) of an adverse exposure of a
genetically pre-disposed fetus to intra-uterine environmental factors.
Exposure to environmental agents during development can result in death,
structural malformation, and/or functional alteration of the embryo/fetus.
These toxicant-induced pathogenic responses are most likely the result of
altered gene expression associated with altered cell production and cell
differentiation involved in the establishment of cell lineages leading to the
structural and functional character of the tissues, organs, and systems that
arise from these lineages.
The NIEHS has a significant program that addresses the role of developmental
exposures on structural malformations i.e., classical birth defects. The new
high-throughput functional-genomic, metabonomic, proteomic, and bioinformatic
technologies now offer for the first time the opportunity to pursue an
understanding of the role of in utero exposures to environmental agents in
causing functional changes in organs and tissues that result in increased
susceptibility to diseases later in life.
The purpose of this program announcement with a set aside of funds and a
Special Emphasis Panel review by the NIH Center for Scientific Review is to
stimulate research in an important and emerging area of developmental
toxicology: the effect of in utero exposures that cause permanent functional
changes that are not overtly, grossly teratogenic and that result in
increased susceptibility to disease/dysfunction later in the life span. It is
becoming increasingly apparent that there is an environmental component to
nearly every disease. In some cases the environmental trigger is an exposure
experienced in the adult environment. However, it is now clear that in many
cases the fetus is more sensitive to the same environmental insults and that
the effect of exposures during development may have a far more detrimental
effect on the etiopathology of the disease, both for the fetus as well as the
adult later in life.
RESEARCH OBJECTIVES
The underlying scientific hypothesis behind the fetal basis of adult diseases
has been developed by epidemiology studies and emphasized by Dr. David Barker
in the United Kingdom. This hypothesis, named the Barker Hypothesis, proposed
that prenatal origins of health and disease is one of the most important
issues that affects our lives and that of our children. Dr. Barker has shown
that during development fetuses respond to severe malnutrition by favoring
the metabolic demands of the growing brain/CNS and heart at the expense of
other tissues. The growing brain/CNS and heart tissue may not, however,
escape entirely unscathed. The long-term consequences of this response are
that the fetus is protected from death, is live-born, but is more prone to
diseases later in life.
The Barker Hypothesis studies concentrated on grossly altered nutrition as
the source of the stress during development. These studies showed via
epidemiology studies that low birth weight, small for gestation age, frank
intra-uterine growth retardation (IUGR) or clinically abnormal thinness at
birth strongly predicts the subsequent occurrence of hypertension,
hyperlipidemia, insulin resistance, type 2 diabetes, ischemic heart disease,
breast cancer or prostate cancer in adult life. Fetuses that are clinically
malnourished during the first trimester of development are three times more
likely to be obese as adults. Evidence has been presented in human
populations that gross, heavy exposure to PM10 air pollution containing
carcinogenic PAHs can be correlated with increased IUGR with a peak impact in
the earlier portion of the first trimester - a most vulnerable period of the
cell lineage expansion, differentiation, and cell interactions events of
organogenesis and first growth.
The concept of fetal programming of structural-functional formations during
development has been proposed to explain these findings and the resultant
research area is referred to as Fetal Basis of Adult Disease (FeBAD)
research. Programming is the term used to describe lifelong changes in
function that follow a particular event in an earlier period of the life
span. While epidemiology studies have identified the phenomenon of metabolic
programming, little is known about the mechanism(s) by which fetal insults
lead to altered programming and to disease later in life. In addition,
emphasis thus far has been on alterations in nutrition during development
with virtually no focus on the role that exposures to environmental agents,
such as air or water pollution, either alone or in combination with
qualitative alterations in macro- or micro-nutrition (i.e. soy protein,
phytoestrogens, isoflavones or other chemicals in herbal supplements or
dietary sources), might have on this phenomenon.
There is, however, evidence that some environmental agents, especially those
with endocrine agonist or antagonist activity, may alter developmental
programming via alteration in gene expression or gene imprinting that do not
result in malformations but in functional deficits that do not become
apparent until later in life.
In the reproductive tract, the classic example of this phenomenon in the
environmental area is the diethylstilbestrol (DES) story. In humans, in utero
exposure to DES leads to an increase in vaginal adenocarcinoma around the
time of puberty. In mice, neonatal DES exposure leads to an increase in
uterine adenocarcinoma in adulthood. While the direct connection has not been
made between in utero programming changes due to DES and later life disease,
it is known that DES (in the animal studies) results in altered gene
expression in the uterus that is irreversible without any noticeable gross
alterations in uterine morphology. Other examples in the reproductive area
include developmental exposures of the monkey to androgens that lead to
polycystic ovary syndrome-like effects in the adult, data (still considered
controversial) showing that environmental estrogens, such as DES,
methoxychlor and bisphenol A, cause alterations in gene expression in the rat
prostate that are irreversible and are correlated with increased prostate
cancer, and data showing a link between in utero exposure to dioxin and
endometriosis later in life in primates and rodents.
Cardiopulmonary diseases in postnatal life have also been linked to prenatal
exposure. The most well known example is the association between low birth
weight (which is associated with poor maternal nutrition and perhaps
corticosteroid exposure) and cardiovascular disease (e.g., myocardial
infarcts) and predictors of future cardiovascular disease, such as
hypertension and atherosclerosis, and complex metabolic disease, such as
diabetes. In addition, studies have shown that maternal smoking is associated
with deficits in lung function and with asthma symptoms in the offspring.
Data indicate that these associations are independent of smoking status after
birth.
Some forms of neurodegenerative disease may have their origins in in utero
exposures. For example, there is preliminary evidence that a bacterial
stimulus (endotoxin) can produce cytokines that impair the development of the
mesencephalic dopaminergic systems during pregnancy. This attenuation of the
dopamine neurons during fetal development leaves the offspring with fewer
dopaminergic neurons at birth and at possible increased risk for Parkinson's
disease in later life. In a similar vein, there is preliminary evidence that
exposure to environmental neurotoxins during dopaminergic development
enhances the susceptibility to accelerated dopaminergic cell death during
aging via the common molecular mechanism(s) of the alteration of
stress-activated signal transduction pathways, expression of differentiation
transcription factors, survival factors or phenotype marker proteins in the
nigral dopaminergic neurons. Similarly there is evidence that in utero
exposure to polycyclic biphenols (PCBs) leads to altered thyroid function and
subsequent learning disabilities later in life. In all instances data are
needed to show that the in utero exposures actually lead to an altered
programming at the molecular level and that the disease/dysfunction is a
direct result, albeit, temporally discordant in its onset and/or progression,
of that altered programming.
Based on the epidemiology data that support the Barker Hypothesis and the
preliminary data showing alterations in gene expression and imprinting due to
in utero exposures to some environmental agents, we propose that exposure to
certain environmental chemicals as well as altered nutrition, or in
combination with altered nutrition, will in some situations, not lead to
easily identifiable structural malformations, but instead to alterations in
developmental programming expressed as a permanently altered gland, organ or
system potential. These states of altered potential would be a result of
changes in gene expression, due to altered imprinting, and the underlining
methylation-related protein-DNA relationships associated with chromatin
remodeling. These effects may occur in a time specific (i.e. vulnerable
window) and tissue specific manner and such alterations may be irreversible.
The end-result is an animal that is sensitized such that it will be more
susceptible to diseases later in life. The environmental insult could act via
a one hit or two/three hit scenario. That is, there could be an in utero
exposure that would lead by itself to pathophysiology later in life or there
could be in utero exposure combined with a neonatal exposure (same or
different compound(s) or adult exposure that would trigger the
pathophysiology. The pathophysiology or functional change that results from
the exposures/insult could lead to: a) the occurrence of a disease that
otherwise would not have happened, b) an increase in risk for a disease that
would normally be of lower prevalence, or c) either an earlier onset of a
disease that would normally have occurred or an exacerbation of the disease.
Finally, the pathophysiology could have a variable latent period from onset
in the neonatal period, to early childhood, to pubertal, to early adulthood
to late adulthood depending on the toxicant, time of exposure and
tissue/organ affected and potentially transgenerational effects.
Research Approaches Relevant to this PA
The very nature of the problem mandates that the studies related to this
initiative, at some time, involve whole animal developmental exposures with
analysis of the fetus, embryo and pups, and well as later life
disease/dysfunction incidence. These analyses can be done using transgenics,
model organisms, or rodent models. Research proposed under this initiative
must use environmentally relevant doses, dose response curves and the
examination of the relationship between the molecular mechanism proposed and
the disease/dysfunction studied. Human studies (clinical or epidemiology) are
not responsive. However, it would be acceptable to propose studies to examine
gene expression using human cells/tissues and as a prelude to future
epidemiology studies.
This initiative also requires the use of the new technologies of gene
expression profiling, and epigenetics (methylation, imprinting and chromatin
remodeling). The use of these technologies allows assessment of in utero
exposure to environmental agents. A critical component of applications to
this Program Announcement is the development of a direct correlation and
eventually a cause and effect relationship between the alterations in gene
expression during development (either increased, decreased or inappropriate
timing) to alterations in signal transduction pathways and alterations in
growth factors and cytokines and hormones that lead to a specific disease or
dysfunction that occurs later in life.
Another critical part of this initiative is the collaboration of
developmental biologists/toxicologists with scientists studying the onset and
exacerbation of adult onset diseases. All applications must show expertise in
both developmental biology/toxicology and disease pathophysiology. In
addition, a specific disease must be the focus of the application with
emphasis on the role of in utero exposure and changes in gene expression in
the fetus to the onset or severity of the disease.
This initiative will focus on only the three areas that have the most
preliminary data and, thus, show the most promise of success: the
reproductive tract, the pulmonocardiovascular system, and the brain/nervous
system.
The diseases of interest to NIEHS with respect to this initiative include
reproductive/hormonal (fertility, endometriosis, fibroids, premature
menopause, polycyclic ovary syndrome, prostate/ovary/breast cancer)
cardiopulmonary (heart disease, atherosclerosis, hypertension, chronic
obstructive pulmonary disease, adult asthma) and brain/CNS (neurodegenerative
diseases - Parkinson's, Alzheimer). It may be possible to submit applications
to this initiative with an emphasis on other diseases as long as they are
related to one or more of the above noted emphasis areas. It should be noted
that these are all adult onset diseases. Thus this initiative has a focus on
diseases that have a long latency. Diseases of childhood or puberty or
diseases of other tissues and organ systems are not responsive to this
specific announcement.
Applicants to this program must link in utero and/or neonatal exposures
during critical windows of development to changes in gene expression that are
tissue specific (reproductive, cardiopulmonary and brain) and irreversible.
These changes in gene expression will then need to be measured in the adult
and correlated with the diseases/dysfunction studied with or without
additional adult exposures.
Applicants may study any environmental agent/chemical/stressor to which there
is human exposure and the potential for in utero exposure. This includes any
endocrine active chemicals and in addition, organic solvents, particulate
matter, pesticides, nutritional supplements, phytochemicals and metals.
Nutrition alone cannot be used as an in utero exposure alone but can be
studied in conjunction with another exposure. Exposure to the environmental
agent must be in utero but may also be neonatal and/or adult.
MECHANISM OF SUPPORT
This PAR will use the NIH exploratory/developmental (R21) award mechanism.
The R21 grant award mechanism supports innovative, high-risk/high-impact
research requiring preliminary testing or development; exploration of the use
of approaches and concepts new to a particular substantive area; research and
development of data upon which significant future research may be built.
Applications will be considered high-impact if they demonstrate the potential
for groundbreaking, precedent setting significance, and high-risk because
they either lack sufficient preliminary date to ensure their feasibility, or
involve the use of a new model system or technique. As an applicant you will
be solely responsible for planning, directing, and executing the proposed
project.
This PAR uses just-in-time concepts. It also uses the modular budgeting
format. (see https://grants.nih.gov/grants/funding/modular/modular.htm).
Specifically, if you are submitting an application with direct costs in each
year of $250,000 or less, use the modular format.
ELIGIBLE INSTITUTIONS
You may submit (an) application(s) if your institution has any of the
following characteristics:
o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals,
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic or foreign
FUNDS AVAILABLE
The NIEHS intends to commit approximately $2 million in FY 2003, 2004 and
2005 to fund new grants in response to this PAR. An applicant for an R21
grant may request a project period of up to three years and a budget for
total direct costs, including third party facilities and administrative
costs, not to exceed $100,000 per year. Because the nature and scope of the
proposed research will vary from application to application, it is
anticipated that the size and duration of each award will also vary. Although
the financial plans of the NIEHS provide support for this program, awards
pursuant to this PAR are contingent upon the availability of funds and the
receipt of a sufficient number of meritorious applications.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
WHERE TO SEND INQUIRIES
We encourage your inquiries concerning this PAR and welcome the opportunity
to answer questions from potential applicants. Inquiries may fall into two
areas: scientific/research, and financial or grants management issues:
o Direct your questions about scientific/research issues related to the
reproductive/endocrine area to:
Jerry Heindel, Ph.D.
Scientific Program Administrator
Organs and Systems Toxicology Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233 (EC-23)
Research Triangle Park, NC 27709
Telephone: 919-541-0781
FAX: 919-541-5064
Email: heindelj@niehs.nih.gov
o Direct your questions about scientific/research issues related to the
cardiopulmonary area to:
J. Patrick Mastin, Ph.D.
Scientific Program Administrator
Organs and Systems Toxicology Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233 (EC-23)
Research Triangle Park, NC 27709
Telephone: 919-541-3289
FAX: 919-541-5064
Email: mastin@niehs.nih.gov
Direct your questions about scientific/research issues related to the
neurodegenerative area to:
Annette Kirshner, Ph.D.
Scientific Program Administrator
Organs and Systems Toxicology Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233 (EC-23)
Research Triangle Park, NC 27709
Telephone: 919 541-0484
FAX: 919-541-5064
Email: kirshner@niehs.nih.gov
o Direct your questions about financial or grants management matters to:
Ms. Lerlita Garcia
Grants Management Specialist
Grants Management Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233 (EC-22)
Research Triangle Park, NC 27709
Telephone: 919-316-4638
FAX: 919-541-2860
Email: garcia@niehs.nih.gov
Although not participating in this PA, the National Institute on Drug
Abuse (NIDA) is interested in funding research aimed at understanding the
physiological and neurobiological consequences of in utero exposure to drugs
of abuse, including inhalants (e.g. Toluene) that may be abused by pregnant
women. NIDA is also interested in understanding the neurobiological
consequences of in utero exposure of environmental chemicals that may confer
risk or vulnerability to substance abuse disorder later in life. For more
information on NIDA's pre-clinical in utero exposure program, please contact
Dr. Pushpa Thadani at 301-443-6300, email: pt24e@nih.gov
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that includes
the following information:
o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this PA
Although a letter of intent is not required, is not binding, and does not
enter into the review of a subsequent application, the information that it
contains allows NIEHS staff to estimate the potential review workload and
plan the review.
The letter of intent is to be sent by the date listed at the beginning of
this document. The letter of intent should be sent to:
Ethel Jackson D.D.S.
Chief, Scientific Review Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233, EC-30
(79 T.W. Alexander Drive, 4401 Bldg, 3rd Floor) express mail
Research Triangle Park, NC 27709
Telephone: 919-541-7846
FAX: 919-541-2503
Email: jackson4@niehs.nih.gov
SUBMITTING AN APPLICATION
Applications must be prepared using the PHS 398 research grant application
instructions and forms (rev. 5/2001). The PHS 398 is available at
https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive
format. For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email: GrantsInfo@nih.gov.
Applicants should note that R21 applications have a page limitation of 15
pages for the Research Plan.
APPLICATION RECEIPT DATES
Applications submitted in response to this PA will be accepted on August 12,
of 2002, 2003 and 2004.
SPECIFIC INSTRUCTIONS FOR MODULAR GRANT APPLICATIONS
Applications requesting up to $250,000 per year in direct costs must be
submitted in a modular grant format. The modular grant format simplifies the
preparation of the budget in these applications by limiting the level of
budgetary detail. Applicants request direct costs in $25,000 modules.
Section C of the research grant application instructions for the PHS 398
(rev. 5/2001) at https://grants.nih.gov/grants/funding/phs398/phs398.html
includes step-by-step guidance for preparing modular grants. Additional
information on modular grants is available at
https://grants.nih.gov/grants/funding/modular/modular.htm.
SENDING AN APPLICATION TO THE NIH
Submit a signed, typewritten original of the application, including the
Checklist, and four signed, photocopies, in one package to:
Center for Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
At the time of submission, one additional copy of the application must be
sent to:
Ethel Jackson D.D.S.
Chief, Scientific Review Branch
Division of Extramural Research and Training
National Institute of Environmental Health Sciences
P.O. Box 12233 (EC-30)
(79 T.W. Alexander Drive, 4401 Bldg, 3rd floor) express mail
Research Triangle Park, NC 27709
Telephone: 919-541-7846
FAX: 919-541-2503
Email: jackson4@niehs.nih.gov
APPLICATION PROCESSING
Applications must be received by or mailed before the receipt dates described
above. The CSR will not accept any application in response to this PA that is
essentially the same as one currently pending initial review unless the
applicant withdraws the pending application. The CSR will not accept any
application that is essentially the same as one already reviewed. This does
not preclude the submission of a substantial revision of an application
already reviewed, but such application must include an Introduction
addressing the previous critique.
PEER REVIEW PROCESS
Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by the NIEHS. Incomplete and/or non-responsive applications
will be returned to the applicant without further consideration.
Applications that are complete and responsive to the PA will be evaluated for
scientific and technical merit by an appropriate peer-review Special Emphasis
Panel convened by the CSR in accordance with the review criteria stated
below. As part of the initial merit review, all applications will:
o Receive a written critique.
o Undergo a process in which only those applications deemed to have the
highest scientific merit, generally the top half of the applications under
review, will be discussed and assigned a priority score.
o Receive a second level review by the NIEHS National Advisory Council.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to discuss the following
aspects of your application in order to judge the likelihood that the
proposed research will have a substantial impact on the pursuit of these
goals:
o Significance
o Approach
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these criteria
in assigning your application's overall score, weighting them as appropriate
for each application. Your application does not need to be strong in all
categories to be judged likely to have major scientific impact and thus
deserve a high priority score. For example, you may propose to carry out
important work that by its nature is not innovative but is essential to move
a field forward.
(1) SIGNIFICANCE: Does your study address an important problem? If the aims
of your application are achieved, how do they advance scientific knowledge?
What will be the effect of these studies on the concepts or methods that
drive this field?
(2) APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well integrated, and appropriate to the aims of the
project? Do you acknowledge potential problem areas and consider alternative
tactics?
(3) INNOVATION: Does your project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does your project challenge
existing paradigms or develop new methodologies or technologies?
(4) INVESTIGATOR: Are you appropriately trained and well suited to carry out
this work? Is the work proposed appropriate to your experience level as the
principal investigator and to that of other researchers (if any)?
(5) ENVIRONMENT: Does the scientific environment in which your work will be
done contribute to the probability of success? Do the proposed experiments
take advantage of unique features of the scientific environment or employ
useful collaborative arrangements? Is there evidence of institutional
support?
For R21 applications, the above stated criteria will be reviewed but it will
be noted that the R21 is a developmental/exploratory grant mechanism that is
used for high risk/high impact projects to generate preliminary data to
develop novel hypotheses. Therefore, review standards for preliminary data
and past performance are not applicable for this mechanism.
RECEIPT AND REVIEW SCHEDULE
Letter of Intent Receipt Date: July 10, 2002, 2003, 2004
Application Receipt Date: August 12, 2002, 2003, 2004
Peer Review Date: November 2002, 2003, 2004
Council Review: February 2003, 2004, 2005
Earliest Anticipated Start Date: April 2003, 2004, 2005
AWARD CRITERIA
Applications submitted in response to a PA will compete for available funds
with all other recommended applications. The following will be considered in
making funding decisions:
o Scientific merit of the proposed project as determined by peer review.
o Availability of funds.
o Relevance to program priorities.
REQUIRED FEDERAL CITATIONS
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT
The Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2)
cited publicly and officially by a Federal agency in support of an action
that has the force and effect of law (i.e., a regulation) may be accessed
through FOIA. It is important for applicants to understand the basic scope of
this amendment. NIH has provided guidance at
https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained within
specified page limitations. Unless otherwise specified in an NIH
solicitation, Internet addresses (URLs) should not be used to provide
information necessary to the review because reviewers are under no obligation
to view the Internet sites. Furthermore, we caution reviewers that their
anonymity may be compromised when they directly access an Internet site.
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a PHS-
led national activity for setting priority areas. This PA is related to one
or more of the priority areas. Potential applicants may obtain a copy of
"Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance No.
93.3113 and 93.114, and is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
Awards are made under authorization of Sections 301 and 405 of the Public
Health Service Act as amended (42 USC 241 and 284) and administered under NIH
grants policies described at https://grants.nih.gov/grants/policy/policy.htm
and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition, Public
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain
facilities (or in some cases, any portion of a facility) in which regular or
routine education, library, day care, health care, or early childhood
development services are provided to children. This is consistent with the
PHS mission to protect and advance the physical and mental health of the
American people.